calico llc logo

Calico LLC.

Calico is a research and development company tackling one of life's greatest mysteries, the biology that controls lifespan. Calico, LLC is a research and development company, focus on development of small molecule drug candidate for the treatment of neurodegenerative disease including Amyotrophic lateral sclerosis (ALS), Parkinsons disease (PD).

Calico, LLC licensed to technology from UC San Francisco (UCSF), a University of California health sciences campus, discovered in the laboratory of Peter Walter, Professor of Biochemistry and Biophysics at UCSF.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.calicolabs.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1180 Veterans Blvd.,CA 094080
South San Francisco
United States
Email
Contact Number

In April 2016, The Jackson Laboratory (JAX), a nonprofit biomedical research institution, and Calico, signed a multi-year collaboration focused on applying mouse genetics to the study of aging. Under the terms, Calico will fund research projects with an option to obtain exclusive rights to discoveries made in these collaborative projects.

In Apr 2015, Calico and the Buck Institute partnered to identify, fund and support research into the basic biology of and potential therapies for age-related diseases.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/calico-life-sciences-llc” connections=”true” suffix=””]

In Sep 2014, Calico and AbbVie collaborated to discover, develop and bring to market therapies for patients with age-related diseases, including for neurodegeneration and cancer. Both will initially provide up to $250Mn each to fund the collaboration and later on contribute an additional $500Mn. In 2018, the collaboration was extended for three more years.

In Mar 2017, Calico and C4 Therapeutics (C4T) collaborated for five years to discover, develop, and commercialize therapies for treating diseases of aging, including cancer. Under agreement it leverage C4Ts expertise and capabilities in targeted protein degradation to jointly discover and advance small molecule protein degraders as therapeutic agent to remove diseases.